Ardelyx, Inc.

Ardelyx, Inc.

ARDXยทNASDAQ

$5.43

-1.5%
HealthcareBiotechnology

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.34B
EPS-0.2600
P/E Ratio-20.90
Earnings Date08/03/2026

No Dividend Yield Data

ARDX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

ARDX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

ARDX has not reported any net dividends paid values in the available annual periods.

Ardelyx, Inc.

Ardelyx, Inc. Dividend History

ARDX ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

ARDX Dividend Payment History

ARDX ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
ardx

Ardelyx, Inc. Payout Ratio Analysis

ARDX ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-61.60M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.